Strategies to Reduce Clostridioides Difficile Infection in Hematologic Malignancies |
0.75 |
10/30/2020 - 12:00am to 10/30/2021 - 12:00am |
Management of Cardiac Complications in Hematologic Malignancies |
0.75 |
10/30/2020 - 12:00am to 10/30/2021 - 12:00am |
Advances and Innovations in Multiple Myeloma |
0.75 |
10/30/2020 - 12:00am to 10/30/2021 - 12:00am |
Lymphoma 101: The Plot Thickens |
0.50 |
10/30/2020 - 12:00am to 10/30/2021 - 12:00am |
Navigating the Jargon of Molecular Testing |
0.50 |
10/30/2020 - 12:00am to 10/30/2021 - 12:00am |
Controversies in the Management of Early-Stage Hodgkin Lymphoma |
0.50 |
10/30/2020 - 12:00am to 10/30/2021 - 12:00am |
Updates in the Management of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Sequencing Therapy and the Role of MRD Testing |
0.50 |
10/30/2020 - 12:00am to 10/30/2021 - 12:00am |
Challenges and Opportunities in Marginal Zone Lymphoma: Implications of Biology on Treatment |
0.50 |
10/30/2020 - 12:00am to 10/30/2021 - 12:00am |
Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma: Is it Time to Consider CAR T for All? |
0.50 |
10/30/2020 - 12:00am to 10/30/2021 - 12:00am |
Peripheral T-Cell Lymphomas-Not Otherwise Specified: A Shrinking Entity? |
0.50 |
10/30/2020 - 12:00am to 10/30/2021 - 12:00am |
Emerging Therapeutic Options in Acute Lymphoblastic Leukemia |
0.50 |
10/30/2020 - 12:00am to 10/30/2021 - 12:00am |
Advances in Acute Myeloid Leukemia (AML) Management: Focus on Secondary AML and Older Patients with AML |
0.50 |
10/30/2020 - 12:00am to 10/30/2021 - 12:00am |
Myeloproliferative Neoplasms: Emerging Treatment Options for Myelofibrosis |
0.50 |
10/30/2020 - 12:00am to 10/30/2021 - 12:00am |
Evolving Concepts in the Diagnosis and Staging of Multiple Myeloma |
0.50 |
10/30/2020 - 12:00am to 10/30/2021 - 12:00am |
Bonanza of New Treatment Regimens for Multiple Myeloma: What is Right for My Patient? |
0.50 |
10/30/2020 - 12:00am to 10/30/2021 - 12:00am |